SCHEMBL16628474

SCHEMBL16628474

C1=CSCS1.c1ccc(Nc2ccccc2Nc2ncncn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL6 P41182 1/20 0.41
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
MAPT P10636 3/20 0.37
KDM4E B2RXH2 2/20 0.37
GAA P10253 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
GLA P06280 1/20 0.37
RECQL P46063 1/20 0.37
PIM1 P11309 3/20 0.36
CDK2 P24941 3/20 0.36
GSK3B P49841 3/20 0.36
CDK5 Q00535 3/20 0.36
CDC7 O00311 2/20 0.36
DAPK3 O43293 2/20 0.36
FLT3 P36888 2/20 0.36
CDK9 P50750 2/20 0.36
DYRK1A Q13627 2/20 0.36
MELK Q14680 2/20 0.36
HIPK2 Q9H2X6 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9325233 0.91 BCL6 (0.49) BCL6MEN1KMT2AMAPTKDM4E
SCHEMBL16628624 0.79 CYP1A2 (0.38) BCL6MEN1KMT2AMAPTKDM4E
SCHEMBL16628623 0.78 TDP1 (0.42) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL10382991 0.78 HTT (0.43) BCL6MEN1KMT2AMAPTPIM1
SCHEMBL609197 0.76 BCL6 (0.57) BCL6MEN1KMT2AMAPTKDM4E
SCHEMBL29134257 0.73 ALDH1A1 (0.56) BCL6MEN1KMT2AMAPTKDM4E
SCHEMBL444976 0.67 MAPT (0.70) MEN1KMT2AMAPTKDM4EGAA
SCHEMBL29477063 0.67 FABP3 (0.46) MEN1KMT2AKDM4EHSD17B10ALDH1A1
SCHEMBL28640878 0.67 MAPT (0.45) BCL6MEN1KMT2AMAPTKDM4E
SCHEMBL4774160 0.66 BCL6 (0.46) BCL6MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3505522-B1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND MORI KUNIO (JP) 2020-10-14 EP disclosed
US-10385076-B2 Surface treatment agent and novel compound Mori, Kunio (JP) 2019-08-20 US disclosed
EP-3505522-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2019-07-03 EP disclosed
EP-2859962-B1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND MORI KUNIO (JP) 2019-01-23 EP disclosed
US-20170334933-A1 SURFACE TREATMENT AGENT AND NOVEL COMPOUND Mori, Kunio (JP) 2017-11-23 US disclosed
US-9790242-B2 Surface treatment method, surface treatment agent, and novel compound Mori, Kunio (JP) 2017-10-17 US disclosed
US-20150152124-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2015-06-04 US disclosed
EP-2859962-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND Mori, Kunio (JP) 2015-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152124-A1 SURFACE TREATMENT METHOD, SURFACE TREATMENT AGENT, AND NOVEL COMPOUND EPCAM, ITGAM, MET BCL6 1975/4885MEN1 1048/4885KMT2A 330/4885
US-20170334933-A1 SURFACE TREATMENT AGENT AND NOVEL COMPOUND EPCAM, MET, ITGAM BCL6 2590/4885MEN1 857/4885KMT2A 502/4885
US-10385076-B2 Surface treatment agent and novel compound EPCAM, MET, ITGAM BCL6 2590/4885MEN1 857/4885KMT2A 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.